Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levofloxacin
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : National Liver Institute, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
Details : Levofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Levofloxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : National Liver Institute, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
